Explore FHI 360

Feature

FHI 360 delivers uninterrupted tuberculosis care during the COVID-19 pandemic

CAP-TB’s emergency response ensures uninterrupted treatment access for multidrug-resistant tuberculosis patients in China during the COVID-19 pandemic.

Publication

Asia Regional Pharmacovigilance Workshop

Materials cover the Asia Regional Pharmacovigilance Workshop: Implementation of Active TB Drug-safety Monitoring and Management for New Drugs and Treatment Regimens for Multidrug-Resistant Tuberculosis.

Past Project

Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center

FHI 360 leads the Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC), which manages worldwide research teams.

Past Project

China Tuberculosis Clinical Trials Consortium (CTCTC) project

FHI 360’s China Tuberculosis Clinical Trials Consortium provides mentoring and advice on the critical aspects of maintaining a successful tuberculosis clinical trial network in China.

You are here

Search FHI 360

Practice Areas

Services

Content Types

Expertise Areas

Countries

Article Types

Resource Types

FHI 360 delivers uninterrupted tuberculosis care during the COVID-19 pandemic

Asia Regional Pharmacovigilance Workshop

Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center

China Tuberculosis Clinical Trials Consortium (CTCTC) project

You are here

Search FHI 360

Practice Areas

Services

Content Types

Expertise Areas

Countries

Article Types

Resource Types

Search within these results

4 Results Found

FHI 360 delivers uninterrupted tuberculosis care during the COVID-19 pandemic

Asia Regional Pharmacovigilance Workshop

Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center

China Tuberculosis Clinical Trials Consortium (CTCTC) project